Skip to main content
SpringerLink
Log in

Regionäre Lymphknotenmetastasen beim malignen Melanom

Adjuvante Strahlentherapie reduziert Rezidivrisiko im Bestrahlungsareal

  • journal club
  • Published:
Info Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Burmeister BH et al. Lancet Oncol. 2012;13(6):589–97.

    Article  PubMed  Google Scholar 

  2. S3-Leitlinie ”Diagnostik, Therapie und Nachsorge des Melanoms“, Version 1.1 - Februar 2013, AWMF-Register-Nummer: 032-024OL.

  3. Eggermont AM et al. Lancet Oncol. 2015;16(5):522–30.

    Article  CAS  PubMed  Google Scholar 

  4. BRIM8: a study of vemurafenib adjuvant therapy in patients with resected cutaneous BRAF mutant melanoma. ClinicalTrials.gov Identifier: NCT01667419.

  5. A study of the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib in the adjuvant treatment of High-risk BRAF V600 mutation-positive melanoma after surgical resection. (COMBI-AD). ClinicalTrials.gov Identifier: NCT01682083.

  6. Study of Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk stage III Melanoma (MK-3475-054/KEYNOTE-054). ClinicalTrials.gov Identifier: NCT02362594.

  7. Efficacy study of nivolumab compared to Ipilimumab in prevention of recurrence of melanoma after complete resection of stage IIIb/c or Stage IV Melanoma (CheckMate 238). ClinicalTrials.gov Identifier: NCT02388906.

  8. Erstpubliziert in Strahlenther Onkol. 2016;192(3):190-2.

Originalie

  • Henderson MA et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16(9):1049-60.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Haut-Tumor-Zentrum Hannover (HTZH), Medizinische Hochschule Hannover, Hannover, Deutschland

    Ralf Gutzmer

  2. Klinik für Strahlentherapie und Spezielle Onkologie, Medizinische Hochschule Hannover, Hannover, Deutschland

    Hans Christiansen

Authors
  1. Ralf Gutzmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans Christiansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ralf Gutzmer.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gutzmer, R., Christiansen, H. Adjuvante Strahlentherapie reduziert Rezidivrisiko im Bestrahlungsareal. Info Onkol. 19, 29–30 (2016). https://doi.org/10.1007/s15004-016-5340-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-016-5340-x

Schlüsselwörter

Search

Navigation